Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (607)

2024

  1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

    Cancers, Vol. 16, Núm. 9

  2. A comprehensive examination of small-bowel capsule endoscopy in Spanish centers to meet European Society of Gastrointestinal Endoscopy standards

    Endoscopy International Open, Vol. 12, Núm. 3, pp. E344-E351

  3. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  4. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  5. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  6. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  7. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  8. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

  9. Accuracy of Smartwatch Electrocardiographic Recording in the Acute Coronary Syndrome Setting: Rationale and Design of the ACS WATCH II Study

    Journal of Clinical Medicine, Vol. 13, Núm. 2

  10. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial

    Intensive Care Medicine, Vol. 50, Núm. 2, pp. 247-257

  11. Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not

    European Urology

  12. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  13. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  14. Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

    Translational Andrology and Urology

  15. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  16. Clinical impact of remote heart failure management using the multiparameter ICD HeartLogic alert

    Revista Espanola de Cardiologia

  17. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  18. Clinical practice guideline on the management of vestibular schwannoma

    Acta Otorrinolaringologica Espanola, Vol. 75, Núm. 2, pp. 108-128

  19. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  20. Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines

    Reports of Practical Oncology and Radiotherapy, Vol. 29, Núm. 3, pp. 340-347